- COMPASS Pathways is a business that is trying to treat a serious form of depression by using psilocybin, which is known for its psychoactive effects.
- COMPASS is looking to treat treatment-resistant depression (TRD), which has 80-90% relapse rate and affects 100 million people worldwide.
- Currently, COMPASS is in their Phase II clinical trials, with results expected to come at the end of FY 2021.
- Until Phase II trials results come out, investors should stay away from COMPASS, for they still have lots to prove before they can even create revenue.
For further details see:
Compass Pathways: Huge Growth Potential, But I'm Cautious